{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:52:16Z","timestamp":1783529536322,"version":"3.55.0"},"reference-count":66,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing, China","doi-asserted-by":"publisher","award":["cstc2021jcyj-msxmX0351"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0351"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing, China","doi-asserted-by":"publisher","award":["cstc2021jcyjmsxmX1116"],"award-info":[{"award-number":["cstc2021jcyjmsxmX1116"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Bladder cancer exhibits substantial heterogeneity encompassing genetic\nexpressions and histological features. This heterogeneity is predominantly attributed to alternative\nsplicing (AS) and AS-regulated splicing factors (SFs), which, in turn, influence bladder\ncancer development, progression, and response to treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed to explore the immune landscape of aberrant AS in bladder cancer\nand establish the prognostic signatures for survival prediction.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Bladder cancer-related RNA-Seq, transcriptome, and corresponding clinical information\nwere downloaded from The Cancer Genome Atlas (TCGA). Gene set enrichment analysis\n(GSEA) was used to identify significantly enriched pathways of cancer-related AS events.\nThe underlying interactions among differentially expressed genes (DEGs) and cancer-related\nAS events were assessed by a protein-protein interaction network. Univariate and multivariate\nCox regression analyses were performed to identify crucial prognostic DEGs that co-occurred\nwith cancer-related AS events (DEGAS) for overall survival. The area under the curve (AUC)\nof receiver operating characteristic (ROC) curves was used to assess the efficiency of the prognostic\nsignatures. The CIBERSORT algorithm was used to explore the abundance of immune\ninfiltrating cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 3755 cancer-related AS events and 3110 DEGs in bladder cancer were identified.\nAmong them, 379 DEGs co-occurred with cancer-related AS events (DEGAS), of which\n102 DEGAS were associated with 14 dysregulated SFs. GSEA and KEGG analysis showed that\ncancer-related AS events were predominantly enriched in pathways related to immunity, tumorigenesis,\nand treatment difficulties of bladder cancer. Multivariate Cox regression analysis identified\n8 DEGAS (CABP1, KCNN2, TNFRSF13B, PCDH7, SNRPA1, APOLD1, CX3CL1, and\nDENND5A) significantly associated with OS, and they were further integrated into the prediction\nmodel with good AUCs at 3-year, 5-year and 7-year ROC curves (all&gt;0.7). Immune infiltration\nanalysis revealed the significant enrichment of three immune cell types (B cells na\u00efve,\ndendritic cells resting, and dendritic cell activated) in high-risk bladder cancer patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This study not only unveiled comprehensive prognostic signatures of AS events in\nbladder cancer but also established a robust prognostic model based on survival-related DEGAS.\nThese aberrant AS events, dysregulated SFs, and the identified 8 DEGAS may have significant\nclinical potential as therapeutic targets for bladder cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748928329276241020184935","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:30:48Z","timestamp":1730269848000},"page":"185-199","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Tumor Immune Infiltration in Bladder Cancer"],"prefix":"10.2174","volume":"20","author":[{"given":"Gao-Lei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, Army Medical Center, Chongqing, 400042, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Army Medical Center, Chongqing, 400042, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Liang","sequence":"additional","affiliation":[{"name":"People\u2019s Hospital of Chong Qing Liang Jiang New Area, Chongqing, 400042,\nChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Army Medical Center, Chongqing, 400042, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Army Medical Center, Chongqing, 400042, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hua","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Urology, Army Medical Center, Chongqing, 400042, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","volume":"8","author":"Saginala K.","year":"2020","unstructured":"Saginala K.; Barsouk A.; Aluru J.S.; Rawla P.; Padala S.A.; Barsouk A.; Epidemiology of bladder cancer. Med Sci (Basel)  2020,8(1),15","journal-title":"Med Sci (Basel)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"Richters A.","year":"2020","unstructured":"Richters A.; Aben K.K.H.; Kiemeney L.A.L.M.; The global burden of urinary bladder cancer: An update. World J Urol  2020,38(8),1895-1904","journal-title":"World J Urol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=4","year":"2024","unstructured":"Key statistics for bladder cancer.  Available from:\n https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html2024"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.mpsur.2019.07.003","volume":"37","author":"Mushtaq J.","year":"2019","unstructured":"Mushtaq J.; Thurairaja R.; Nair R.; Bladder cancer. Surgery  2019,37(9),529-537","journal-title":"Surgery"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2011.1142","volume":"306","author":"Freedman N.D.","year":"2011","unstructured":"Freedman N.D.; Silverman D.T.; Hollenbeck A.R.; Schatzkin A.; Abnet C.C.; Association between smoking and risk of bladder cancer among men and women. JAMA  2011,306(7),737-745","journal-title":"JAMA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e004128","DOI":"10.1136\/bmjgh-2020-004128","volume":"6","author":"Safiri S.","year":"2021","unstructured":"Safiri S.; Kolahi A.A.; Naghavi M.; Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990\u20132019: A systematic analysis for the global burden of disease study 2019. BMJ Glob Health  2021,6(11),e004128","journal-title":"BMJ Glob Health"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.31557\/APJCP.2021.22.10.3385","volume":"22","author":"Abdolahinia Z.","year":"2021","unstructured":"Abdolahinia Z.; Pakmanesh H.; Mirzaee M.; Bazrafshan A.; Shafiei Bafti M.; Shahesmaeili A.; Opium and cigarette smoking are independently associated with bladder cancer: The findings of a matched case - Control study. Asian Pac J Cancer Prev  2021,22(10),3385-3391","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2217\/pme.11.15","volume":"8","author":"Gu J.","year":"2011","unstructured":"Gu J.; Wu X.; Genetic susceptibility to bladder cancer risk and outcome. Per Med  2011,8(3),365-374","journal-title":"Per Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12013-015-0574-z","volume":"73","author":"Zhang X.","year":"2015","unstructured":"Zhang X.; Zhang Y.; Bladder cancer and genetic mutations. Cell Biochem Biophys  2015,73(1),65-69","journal-title":"Cell Biochem Biophys"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.3390\/ijms22094483","volume":"22","author":"Wigner P.","year":"2021","unstructured":"Wigner P.; Gr\u0119bowski R.; Bijak M.; Saluk-Bijak J.; Szemraj J.; The interplay between oxidative stress, inflammation and angiogenesis in bladder cancer development. Int J Mol Sci  2021,22(9),4483","journal-title":"Int J Mol Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s43141-021-00182-7","volume":"19","author":"Khalifa M.K.","year":"2021","unstructured":"Khalifa M.K.; Bakr N.M.; Ramadan A.; Implications of targeted next-generation sequencing for bladder cancer: Report of four cases. J Genet Eng Biotechnol  2021,19(1),91","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.molcel.2019.09.017","volume":"76","author":"Ule J.","year":"2019","unstructured":"Ule J.; Blencowe B.J.; Alternative splicing regulatory networks: Functions, mechanisms, and evolution. Mol Cell  2019,76(2),329-345","journal-title":"Mol Cell"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00439-017-1790-y","volume":"136","author":"Gallego-Paez L.M.","year":"2017","unstructured":"Gallego-Paez L.M.; Bordone M.C.; Leote A.C.; Saraiva-Agostinho N.; Ascens\u00e3o-Ferreira M.; Barbosa-Morais N.L.; Alternative splicing: The pledge, the turn, and the prestige. Hum Genet  2017,136(9),1015-1042","journal-title":"Hum Genet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/463786","volume":"2013","author":"Ladomery M.","year":"2013","unstructured":"Ladomery M.; Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol  2013,2013,1-6","journal-title":"Int J Cell Biol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"Bonnal S.C.","year":"2020","unstructured":"Bonnal S.C.; L\u00f3pez-Oreja I.; Valc\u00e1rcel J.; Roles and mechanisms of alternative splicing in cancer \u2014 Implications for care. Nat Rev Clin Oncol  2020,17(8),457-474","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","volume":"13","author":"Craene B.D.","year":"2013","unstructured":"Craene B.D.; Berx G.; Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer  2013,13(2),97-110","journal-title":"Nat Rev Cancer"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","volume":"6","author":"Zhang Y.","year":"2021","unstructured":"Zhang Y.; Qian J.; Gu C.; Yang Y.; Alternative splicing and cancer: A systematic review. Signal Transduct Target Ther  2021,6(1),78","journal-title":"Signal Transduct Target Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2174\/1568009620666200619123725","volume":"20","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Zhang H.; Jiao B.; The roles of alternative splicing in tumor-immune cell interactions. Curr Cancer Drug Targets  2020,20(10),729-740","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41568-020-0285-7","volume":"45","author":"Park J.","year":"2023","unstructured":"Park J.; Park J.; Chung Y.J.; Alternative splicing: A new breakthrough for understanding tumorigenesis and potential clinical applications. Genes Genomics  2023,45(4),393-400","journal-title":"Genes Genomics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fonc.2019.01270","volume":"2537","author":"Centa J.L.","year":"2022","unstructured":"Centa J.L.; Hastings M.L.; Targeting alternative splicing for therapeutic interventions. Methods Mol Biol  2022,2537,21-36","journal-title":"Methods Mol Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"vbae080","DOI":"10.1016\/j.eururo.2019.01.011","volume":"4","author":"Lang F.","year":"2024","unstructured":"Lang F.; Sorn P.; Suchan M.; Prediction of tumor-specific splicing from somatic mutations as a source of neoantigen candidates. Bioinform Adv  2024,4(1),vbae080","journal-title":"Bioinform Adv"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/2162402X.2018.1474317","volume":"20","author":"Bruni D.","year":"2020","unstructured":"Bruni D.; Angell H.K.; Galon J.; The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer  2020,20(11),662-680","journal-title":"Nat Rev Cancer"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1093\/bioinformatics\/bts452","volume":"28","author":"Ryan M.C.","year":"2012","unstructured":"Ryan M.C.; Cleland J.; Kim R.; Wong W.C.; Weinstein J.N.; SpliceSeq: A resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics  2012,28(18),2385-2387","journal-title":"Bioinformatics"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"D1018","DOI":"10.1093\/nar\/gkv1288","volume":"44","author":"Ryan M.","year":"2016","unstructured":"Ryan M.; Wong W.C.; Brown R.; TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res  2016,44(D1),D1018-D1022","journal-title":"Nucleic Acids Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/bioinformatics\/btv557","volume":"32","author":"Franz M.","year":"2016","unstructured":"Franz M.; Lopes C.T.; Huck G.; Dong Y.; Sumer O.; Bader G.D.; Cytoscape.js: A graph theory library for visualisation and analysis. Bioinformatics  2016,32(2),309-311","journal-title":"Bioinformatics"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"D561","DOI":"10.1093\/nar\/gkq973","volume":"39","author":"Szklarczyk D","year":"2011","unstructured":"Szklarczyk D; Franceschini A; Kuhn M; The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res  2011,39(Database),D561-8","journal-title":"Nucleic Acids Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"D125","DOI":"10.1093\/nar\/gks997","volume":"41","author":"Giulietti M.","year":"2013","unstructured":"Giulietti M.; Piva F.; D\u2019Antonio M.; SpliceAid-F: A database of human splicing factors and their RNA-binding sites. Nucleic Acids Res  2013,41(D1),D125-D131","journal-title":"Nucleic Acids Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"Newman A.M.","year":"2015","unstructured":"Newman A.M.; Liu C.L.; Green M.R.; Robust enumeration of cell subsets from tissue expression profiles. Nat Methods  2015,12(5),453-457","journal-title":"Nat Methods"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"Chen B.","year":"2018","unstructured":"Chen B.; Khodadoust M.S.; Liu C.L.; Newman A.M.; Alizadeh A.A.; Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol  2018,1711,243-259","journal-title":"Methods Mol Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.devcel.2017.10.027","volume":"43","author":"Bajikar S.S.","year":"2017","unstructured":"Bajikar S.S.; Wang C.C.; Borten M.A.; Pereira E.J.; Atkins K.A.; Janes K.A.; Tumor-suppressor inactivation of gdf11 occurs by precursor sequestration in triple-negative breast cancer. Dev Cell  2017,43(4),418-435.e13","journal-title":"Dev Cell"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"7648","DOI":"10.7150\/thno.36585","volume":"9","author":"Li Z.X.","year":"2019","unstructured":"Li Z.X.; Zheng Z.Q.; Wei Z.H.; Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics  2019,9(25),7648-7665","journal-title":"Theranostics"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e957981","DOI":"10.4161\/23723548.2014.957981","volume":"1","author":"Hong S.","year":"2014","unstructured":"Hong S.; Huang Y.; Cao Y.; Chen X.; Han J.D.J.; Approaches to uncovering cancer diagnostic and prognostic molecular signatures. Mol Cell Oncol  2014,1(2),e957981","journal-title":"Mol Cell Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12885-019-5677-2","volume":"19","author":"Van Hoeck A.","year":"2019","unstructured":"Van Hoeck A.; Tjoonk N.H.; van Boxtel R.; Cuppen E.; Portrait of a cancer: Mutational signature analyses for cancer diagnostics. BMC Cancer  2019,19(1),457","journal-title":"BMC Cancer"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","volume":"12","author":"Malone E.R.","year":"2020","unstructured":"Malone E.R.; Oliva M.; Sabatini P.J.B.; Stockley T.L.; Siu L.L.; Molecular profiling for precision cancer therapies. Genome Med  2020,12(1),8","journal-title":"Genome Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-36667-4_1","volume":"1231","author":"Conroy M.J.","year":"2020","unstructured":"Conroy M.J.; Lysaght J.; CX3CL1 signaling in the tumor microenvironment. Adv Exp Med Biol  2020,1231,1-12","journal-title":"Adv Exp Med Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3892\/ijo.2018.4487","volume":"53","author":"Liu P.","year":"2018","unstructured":"Liu P.; Liang Y.; Jiang L.; Wang H.; Wang S.; Dong J.; CX3CL1\/fractalkine enhances prostate cancer spinal metastasis by activating the Src\/FAK pathway. Int J Oncol  2018,53(4),1544-1556","journal-title":"Int J Oncol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12094-020-02431-6","volume":"23","author":"Liu Y.","year":"2021","unstructured":"Liu Y.; Ma H.; Dong T.; Yan Y.; Sun L.; Wang W.; Clinical significance of expression level of CX3CL1\u2013CX3CR1 axis in bone metastasis of lung cancer. Clin Transl Oncol  2021,23(2),378-388","journal-title":"Clin Transl Oncol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"114175","DOI":"10.1016\/j.jep.2021.114175","volume":"275","author":"Que Z.J.","year":"2021","unstructured":"Que Z.J.; Yao J.L.; Zhou Z.Y.; Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs. J Ethnopharmacol  2021,275,114175","journal-title":"J Ethnopharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.7150\/jca.26497","volume":"9","author":"Liang Y.","year":"2018","unstructured":"Liang Y.; Yi L.; Liu P.; CX3CL1 involves in breast cancer metastasizing to the spine via the Src\/FAK signaling pathway. J Cancer  2018,9(19),3603-3612","journal-title":"J Cancer"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/jso.23095","volume":"106","author":"Park M.H.","year":"2012","unstructured":"Park M.H.; Lee J.S.; Yoon J.H.; High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor\u2010infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol  2012,106(4),386-392","journal-title":"J Surg Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"752860","DOI":"10.3389\/fonc.2021.752860","volume":"11","author":"Jiang G.","year":"2021","unstructured":"Jiang G.; Wang H.; Huang D.; The clinical implications and molecular mechanism of CX3CL1 expression in urothelial bladder cancer. Front Oncol  2021,11,752860","journal-title":"Front Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"e150483","DOI":"10.1172\/jci.insight.150483","volume":"6","author":"de Mattos Barbosa M.G.","year":"2021","unstructured":"de Mattos Barbosa M.G.; Lefferts A.R.; Huynh D.; TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI Insight  2021,6(17),e150483","journal-title":"JCI Insight"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"642170","DOI":"10.3389\/fonc.2021.642170","volume":"11","author":"Hinterleitner C.","year":"2021","unstructured":"Hinterleitner C.; Zhou Y.; Tandler C.; Platelet-expressed TNFRSF13B (TACI) predicts breast cancer progression. Front Oncol  2021,11,642170","journal-title":"Front Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"154790","DOI":"10.1016\/j.cyto.2019.154790","volume":"125","author":"Abo-Elfadl M.T.","year":"2020","unstructured":"Abo-Elfadl M.T.; Gamal-Eldeen A.M.; Ismail M.F.; Shahin N.N.; Silencing of the cytokine receptor TNFRSF13B: A new therapeutic target for triple-negative breast cancer. Cytokine  2020,125,154790","journal-title":"Cytokine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1073\/pnas.1220847110","volume":"110","author":"Li C.","year":"2013","unstructured":"Li C.; Enomoto M.; Rossi A.M.; CaBP1, a neuronal Ca 2+ sensor protein, inhibits inositol trisphosphate receptors by clamping intersubunit interactions. Proc Natl Acad Sci USA  2013,110(21),8507-8512","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1093\/brain\/awaa346","volume":"143","author":"Mochel F.","year":"2020","unstructured":"Mochel F.; Rastetter A.; Ceulemans B.; Variants in the SK2 channel gene (KCNN2) lead to dominant neurodevelopmental movement disorders. Brain  2020,143(12),3564-3573","journal-title":"Brain"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3892\/etm.2019.7975","volume":"18","author":"Li L.","year":"2019","unstructured":"Li L.; Liu X.; Ma X.; Identification of key candidate genes and pathways in glioblastoma by integrated bioinformatical analysis. Exp Ther Med  2019,18(5),3439-3449","journal-title":"Exp Ther Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.18632\/aging.202387","volume":"13","author":"Yuan P.","year":"2021","unstructured":"Yuan P.; Ling L.; Gao X.; Identification of RNA-binding protein SNRPA1 for prognosis in prostate cancer. Aging (Albany NY)  2021,13(2),2895-2911","journal-title":"Aging (Albany NY)"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"BSR20193815","DOI":"10.1042\/BSR20193815","volume":"40","author":"Feng J.","year":"2020","unstructured":"Feng J.; Guo J.; Zhao P.; Shen J.; Chai B.; Wang J.; mTOR up-regulation of SNRPA1 contributes to hepatocellular carcinoma development. Biosci Rep  2020,40(6),BSR20193815","journal-title":"Biosci Rep"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"109076","DOI":"10.1016\/j.biopha.2019.109076","volume":"117","author":"Zeng Q.","year":"2019","unstructured":"Zeng Q.; Lei F.; Chang Y.; An oncogenic gene, SNRPA1, regulates PIK3R1, VEGFC, MKI67, CDK1 and other genes in colorectal cancer. Biomed Pharmacother  2019,117,109076","journal-title":"Biomed Pharmacother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.2147\/CMAR.S298072","volume":"13","author":"Zhang S.","year":"2021","unstructured":"Zhang S.; Fu X.; The clinical significance and biological function of PCDH7 in cervical cancer. Cancer Manag Res  2021,13,3841-3847","journal-title":"Cancer Manag Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"28384","DOI":"10.18632\/oncotarget.8635","volume":"7","author":"Lin Y.L.","year":"2016","unstructured":"Lin Y.L.; Wang Y.L.; Fu X.L.; Li W.P.; Wang Y.H.; Ma J.G.; Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer. Oncotarget  2016,7(19),28384-28392","journal-title":"Oncotarget"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s41065-020-00152-y","volume":"157","author":"Chen L.","year":"2020","unstructured":"Chen L.; Xiang Z.; Chen X.; Zhu X.; Peng X.; A seven-gene signature model predicts overall survival in kidney renal clear cell carcinoma. Hereditas  2020,157(1),38","journal-title":"Hereditas"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"854","DOI":"10.18632\/oncoscience.107","volume":"1","author":"Li Y.","year":"2014","unstructured":"Li Y.; Xu J.; Xiong H.; Cancer driver candidate genes AVL9, DENND5A and NUPL1 contribute to MDCK cystogenesis. Oncoscience  2014,1(12),854-865","journal-title":"Oncoscience"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"Lamm D.L.","year":"2000","unstructured":"Lamm D.L.; Blumenstein B.A.; Crissman J.D.; Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol  2000,163(4),1124-1129","journal-title":"J Urol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12865-016-0174-8","volume":"17","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Yang W.; Zhao L.; Immune analysis of expression of IL-17 relative ligands and their receptors in bladder cancer: Comparison with polyp and cystitis. BMC Immunol  2016,17(1),36","journal-title":"BMC Immunol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1084\/jem.20090207","volume":"206","author":"Wang L.","year":"2009","unstructured":"Wang L.; Yi T.; Kortylewski M.; Pardoll D.M.; Zeng D.; Yu H.; IL-17 can promote tumor growth through an IL-6\u2013Stat3 signaling pathway. J Exp Med  2009,206(7),1457-1464","journal-title":"J Exp Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e001895","DOI":"10.1136\/jitc-2020-001895","volume":"9","author":"Liu C.","year":"2021","unstructured":"Liu C.; Liu R.; Wang B.; Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer  2021,9(1),e001895","journal-title":"J Immunother Cancer"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2592419","volume":"2019","author":"Guo F.F.","year":"2019","unstructured":"Guo F.F.; Cui J.W.; The role of tumor-infiltrating B cells in tumor immunity. J Oncol  2019,2019,1-9","journal-title":"J Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-030-49270-0_2","volume":"1273","author":"Kohli K.","year":"2020","unstructured":"Kohli K.; Pillarisetty V.G.; Dendritic cells in the tumor microenvironment. Adv Exp Med Biol  2020,1273,29-38","journal-title":"Adv Exp Med Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e8485","DOI":"10.1371\/journal.pone.0008485","volume":"4","author":"Corcione A.","year":"2009","unstructured":"Corcione A.; Ferretti E.; Bertolotto M.; CX3CR1 is expressed by human B lymphocytes and mediates [corrected] CX3CL1 driven chemotaxis of tonsil centrocytes. PLoS One  2009,4(12),e8485","journal-title":"PLoS One"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3390\/cells8091099","volume":"8","author":"Sutti S.","year":"2019","unstructured":"Sutti S.; Bruzz\u00ec S.; Heymann F.; CX3CR1 mediates the development of monocyte-derived dendritic cells during hepatic inflammation. Cells  2019,8(9),1099","journal-title":"Cells"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1042\/CS20171025","volume":"131","author":"Sutti S.","year":"2017","unstructured":"Sutti S.; Heymann F.; Bruzz\u00ec S.; CX3CR1 modulates the anti-inflammatory activity of hepatic dendritic cells in response to acute liver injury. Clin Sci (Lond)  2017,131(17),2289-2301","journal-title":"Clin Sci (Lond)"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1111\/febs.16133","volume":"288","author":"Wu L.","year":"2021","unstructured":"Wu L.; Lian W.; Zhao L.; Calcium signaling in cancer progression and therapy. FEBS J  2021,288(21),6187-6205","journal-title":"FEBS J"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.4251\/wjgo.v12.i11.1255","volume":"12","author":"Sheng Q.J.","year":"2020","unstructured":"Sheng Q.J.; Tian W.Y.; Dou X.G.; Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma. World J Gastrointest Oncol  2020,12(11),1255-1271","journal-title":"World J Gastrointest Oncol"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928329276241020184935","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235853\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928329276241020184935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:44:48Z","timestamp":1743147888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235853\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748928329276241020184935","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}